Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Rivazest 20 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Rivazest 20

Approved

STANDARD

Rivazest 20

Cipla Limited Indore SEZ (Unit IV)🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 3e9524450e3409cb
Company: Cipla Limited Indore SEZ (Unit IV)
Type: Standard

Approval Details

Approval Id: 3e9524450e3409cb
Drug Approval Philippines Name: Rivazest 20
Product Name: Rivazest 20
Registration Number: DRP-13321
Brand Name: Rivazest 20
Generic Name: Rivaroxaban
Dosage Form: Film-Coated Tablet
Dosage Strength: 20 mg
Manufacturer: Cipla Limited Indore SEZ (Unit IV)
Importer: SMHP Pharmaceuticals Incorporated
Distributor: SMHP Pharmaceuticals Incorporated
Issuance Date: 26 January 2023
Expiry Date: 26 January 2028
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

3e9524450e3409cb

Type

Standard

Back to Philippines FDA Approvals